Quince Therapeutics (QNCX) LD Micro Main Event XVII summary

Clinical development and pipeline progress

• Pivotal phase III NEAT study of EryDex for ataxia telangiectasia (A-T) is underway, with topline results expected in Q4 2025 and cash runway extending into 2026.

• EryDex leverages proprietary AIDE technology, encapsulating dexamethasone in autologous red blood cells to reduce toxicity and enable chronic steroid therapy without typical adverse effects.

• Prior phase III data in A-T showed strong efficacy in the 6–9 age subgroup, guiding the current study's focus, with no serious safety concerns over 3+ years.

• The study is risk-mitigated under FDA Special Protocol Assessment, with Fast Track and orphan drug designations from FDA and EMA.

• Duchenne muscular dystrophy (DMD) selected as the second indication, with proof-of-concept studies planned for 2024–2025.

Market opportunity and commercial strategy

• A-T represents a $1 billion+ commercial opportunity, with 10,000 diagnosed patients across the US and EU5.

• No approved treatments or late-stage competitors for A-T; first-to-market potential is high.

• Pricing strategy informed by recent rare disease approvals, with minimal cost of goods and strong payer/physician support.

• Manufacturing infrastructure is highly scalable, with low direct costs and global IP exclusivity until at least 2034.

• Plans to outlicense ex-U.S. rights to fund further development and commercialization.

Technology platform and intellectual property

• AIDE technology enables point-of-care drug encapsulation, supporting a broad pipeline of rare disease indications.

• IP exclusivity extends globally to 2034 and in the U.S. to 2035; CE marked in Europe.

• EryDex has over 6,000 doses administered, several hundred patient-years of safety data, and over 270 patients treated to date.

• Platform supports expansion into neuromuscular, autoimmune, rheumatology, and hematology rare diseases.

• Numerical ranking of future indications completed, with a focus on severe rare diseases.